Mohammed Abdulhameed Younis

Aspirin (ASA) is the antiplatelet drug that is given to patients the majority of the time. Although there is a considerable body of evidence that supports the efficacy of aspirin in the secondary prevention of ischemic events in persons who already have cardiovascular disease, the function that aspirin plays in primary prevention has been a subject of debate for decades. There has only been a slight reduction in the number of ischemic events, notably myocardial infarction and, to a lesser extent, stroke, which is associated by an increased risk of hemorrhage. This is the only thing that has been determined by historical studies. It is because of these discoveries that professional organizations have come up with a variety of recommendations for the utilization of ASA for the primary prevention of symptoms associated with cardiovascular disease. Recent findings from three primary prevention trials indicate that there are either no benefits or only slight benefits on combined ischemic endpoints. Furthermore, there is no effect on serious cardiovascular events such as myocardial infarction or stroke, and there is an increased risk of bleeding. Over the course of the study, it was determined that the use of aspirin in people who did not have any obvious signs of cardiovascular disease was either associated with a net benefit that was neutral or even a net disadvantage. As a direct result of these findings, the recommendations that are currently in place regarding the utilization of ASA in primary prevention have been subjected to a reevaluation. The purpose of this article is to provide a comprehensive assessment of the existing body of evidence about the utilization of aspirin as a major preventative therapy for cardiovascular disease. With each and every dosage of aspirin, there is a possibility of experiencing bleeding. When compared to people who do not use the substance, those who use 75 milligrams per day have a risk of upper gastrointestinal bleeding that is twice as high. Nano emulsions, also known as NEs, are a type of emulsion system that is defined by the careful distribution of oil or water droplets in the opposing phase, which is stabilized by an appropriate surfactant. The droplet sizes of the individual droplets are in the nanoscale range.

This investigation investigates the impact of oral aspirin and aspirin nanoparticles on the parameters of the complete blood count (CBC) in the rodent. The results indicate that rodents that were administered aspirin experienced significant hematological changes, with the nanoparticle-treated cohort exhibiting partial normalization.

DOI: 10.22271/23940522.2025.v12.i4b.1120

Pages: 127-130  |  180 Views  26 Downloads